IPR Tracker: IPR2016-00912, IPR2016-00915, and IPR2016-00916 (Swiss Pharma Int’l AG) (U.S. Patents Nos. 8,815,236, 8,349,321, and 8,900,577) (Tysabri patents)

PTAB + IPR

IPR2016-00912 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,815,236)

  • Petitioner: Swiss Pharma Int’l AG
  • Patent: U.S. Patent No. 8,815,236
  • Patent Title: Method of Treating Multiple Sclerosis and Crohn’s Disease
  • Patent Assignee: Biogen Idec MA, Inc.

IPR2016-00915 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,349,321)

  • Petitioner: Swiss Pharma Int’l AG
  • Patent: U.S. Patent No. 8,349,321
  • Patent Title: Immunoglobulin Formulation and Method of Preparation Thereof
  • Patent Assignee: Elan Pharmaceuticals, Inc.

IPR2016-00916 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,900,577)

  • Petitioner: Swiss Pharma Int’l AG
  • Patent: U.S. Patent No. 8,900,577
  • Patent Title: Immunoglobulin Formulation and Method of Preparation Thereof
  • Patent Assignee: Biogen Idec MA, Inc.
Download PDF

Tagged with 

Comments are closed.